Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent  

作　　者：Eduardo Mansilla Ricardo Rangel Martínez Gustavo Horacio Marín Idiberto Zotarelli Filho Elsa Rivas Jaime Rivas Katherine Athayde Teixeira de Carvalho Mohammad Reza Dayer Alí Samadikuchaksaraei Eduardo Mansilla;Ricardo Rangel Martínez;Gustavo Horacio Marín;Idiberto Zotarelli Filho;Elsa Rivas;Jaime Rivas;Katherine Athayde Teixeira de Carvalho;Mohammad Reza Dayer;Alí Samadikuchaksaraei(Internal Medicine, School of Medical Sciences, UNLP, La Plata, Argentina;ExomePharma, Ciudad de México DF, México;Pharmacology, School of Medical Sciences, UNLP, La Plata, Argentina;Faceres Medical School, Sao José do Rio Preto, Sao Paulo, Brazil;Intensive Care Units-Hospital de la Amistad Perú Corea II, Santa Rosa and Salvador University Hospital, Piura, Perú;Intensive Care Unit, Hospital de la Amistad Perú Corea II, Santa Rosa, Piura, Perú;Pequeno Príncipe Faculty & Pelé Pequeno Príncipe Institute, Curitiba, Paraná, Brazil;Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran;Department of Tissue Engineering & Regenerative Medicine, Iran University of Medical Sciences, Tehran, Iran)

机构地区：[1]Internal Medicine, School of Medical Sciences, UNLP, La Plata, Argentina [2]ExomePharma, Ciudad de México DF, México [3]Pharmacology, School of Medical Sciences, UNLP, La Plata, Argentina [4]Faceres Medical School, Sao José do Rio Preto, Sao Paulo, Brazil [5]Intensive Care Units-Hospital de la Amistad Perú Corea II, Santa Rosa and Salvador University Hospital, Piura, Perú [6]Intensive Care Unit, Hospital de la Amistad Perú Corea II, Santa Rosa, Piura, Perú [7]Pequeno Príncipe Faculty & Pelé Pequeno Príncipe Institute, Curitiba, Paraná, Brazil [8]Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran [9]Department of Tissue Engineering & Regenerative Medicine, Iran University of Medical Sciences, Tehran, Iran

出　　处：《Pharmacology & Pharmacy》2020年第6期85-104,共20页药理与制药（英文）

摘　　要：SARS-CoV-2 is a novel RNA coronavirus responsible of a deadly pandemic: the clinical illness COVID-19. With only one authorized drug for emergency use in critically ill patients: Remdesivir, there is not any other approved drug or vaccine yet with proven potential to overcome this infection. We exposed here many scientific evidences to support our novel idea that a macrolide, basically Clarithromycin, could be effective as a single agent for treatment and prophylaxis of COVID-19. Clarithromycin could change the history of this pandemic. It could reduce the costs of treatment and the potential adverse effects when combining more than one drug such as with Hydroxychloroquine. Clarithromycin treatment and prophylaxis as a single agent could be much more simple, safe and cheaper as giving Chloroquine or Hydroxychloroquine alone or in combination with Azithromycin as well as other therapeutic options.SARS-CoV-2 is a novel RNA coronavirus responsible of a deadly pandemic: the clinical illness COVID-19. With only one authorized drug for emergency use in critically ill patients: Remdesivir, there is not any other approved drug or vaccine yet with proven potential to overcome this infection. We exposed here many scientific evidences to support our novel idea that a macrolide, basically Clarithromycin, could be effective as a single agent for treatment and prophylaxis of COVID-19. Clarithromycin could change the history of this pandemic. It could reduce the costs of treatment and the potential adverse effects when combining more than one drug such as with Hydroxychloroquine. Clarithromycin treatment and prophylaxis as a single agent could be much more simple, safe and cheaper as giving Chloroquine or Hydroxychloroquine alone or in combination with Azithromycin as well as other therapeutic options.

关 键 词：COVID-19 MACROLIDES CLARITHROMYCIN Single Agent Therapy PROPHYLAXIS 

分 类 号：TP3[自动化与计算机技术—计算机科学与技术]